行情

ABIO

ABIO

方舟生物医药
NASDAQ

实时行情|Nasdaq Last Sale

5.33
+0.23
+4.45%
交易中 12:41 11/12 EST
开盘
5.10
昨收
5.10
最高
5.39
最低
5.07
成交量
4.02万
成交额
--
52周最高
20.45
52周最低
4.725
市值
849.16万
市盈率(TTM)
-0.7635
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ABIO 新闻

  • ARCA biopharma EPS beats by $0.54
  • seekingalpha.5天前
  • ARCA biopharma Q3 EPS $(0.76) Up From $(2.06) YoY
  • Benzinga.5天前
  • ARCA Biopharma Announces Third Quarter 2019 Financial Results and Provides Corporate Update
  • GlobeNewswire.5天前
  • Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Invest In Growth?
  • Simply Wall St..11/03 13:47

更多

所属板块

制药
+0.60%
制药与医学研究
+0.48%

热门股票

名称
价格
涨跌幅

ABIO 简况

ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.
展开

Webull提供Arca Biopharma Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。